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Background: Longitudinal studies of the lung microbiome are challenging due to the invasive nature of sample
collection. In addition, studies of the lung microbiome in human disease are usually performed after disease onset,
limiting the ability to determine early events in the lung. We used a non-human primate model to assess lung
microbiome alterations over time in response to an HIV-like immunosuppression and determined impact of the
lung microbiome on development of obstructive lung disease. Cynomolgous macaques were infected with the
SIV-HIV chimeric virus SHIV89.6P. Bronchoalveolar lavage fluid samples were collected pre-infection and every
4 weeks for 53 weeks post-infection. The microbiota was characterized at each time point by 16S ribosomal RNA
(rRNA) sequencing.
Results: We observed individual variation in the composition of the lung microbiota with a proportion of the
macaques having Tropheryma whipplei as the dominant organism in their lungs. Bacterial communities varied over
time both within and between animals, but there did not appear to be a systematic alteration due to SHIV
infection. Development of obstructive lung disease in the SHIV-infected animals was characterized by a relative
increase in abundance of oral anaerobes. Network analysis further identified a difference in community composition
that accompanied the development of obstructive disease with negative correlations between members of the
obstructed and non-obstructed groups. This emphasizes how species shifts can impact multiple other species,
potentially resulting in disease.
Conclusions: This study is the first to investigate the dynamics of the lung microbiota over time and in response to
immunosuppression in a non-human primate model. The persistence of oral bacteria in the lung and their
association with obstruction suggest a potential role in pathogenesis. The lung microbiome in the non-human
primate is a valuable tool for examining the impact of the lung microbiome in human health and disease.
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sectional analyses due to the invasive nature of bron-
choscopy or lung tissue collection. In addition, study of
the lung microbiome in individuals with lung disease oc-
curs primarily after disease is already manifest, limiting
the ability to investigate changes in the microbiome that
occur early in the disease process.
Animal models allow for serial sampling of the lung
both before and after development of disease. Non-
human primates (NHPs) such as rhesus macaques are
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microbiome composition of NHP is more similar to the
one seen in humans [1]; (b) NHPs are, like humans,
outbred; (c) longitudinal measurements before and after
infection or disease development can more easily be ob-
tained than for humans; and (d) confounding variables
such as smoking or diet can be controlled. While the
monkey gut, oral cavity, and vagina have been surveyed
for microbiome studies [2–4], no work has previously
been done on the lung microbiome of NHPs. Here, we
used cynomolgous macaques as an NHP model to deter-
mine longitudinal changes of the lung microbiome, in-
cluding alterations occurring during a chronic HIV-like
infection and in association with the development of
chronic obstructive pulmonary disease (COPD).
Both local and systemic diseases may have an impact
on the lung microbiome. For example, immune dysfunc-
tion that occurs in HIV infection could lead to microbial
differences in the lung. A recent study demonstrated
that Tropheryma whipplei was present more frequently
in HIV-infected individuals than in HIV-uninfected, sug-
gesting a correlation between bacterial lung residents
and HIV infection [5]. Lung diseases such as COPD have
been postulated to result in shifts in the lung micro-
biome [6–8], but the point at which these changes occur
during the disease process is unknown. COPD is also a
common complication in HIV-infected individuals, with
estimates of a prevalence of 10–20 % depending on the
population studies [9–11]. Macaques infected with a
SIV-HIV chimeric virus (that replicates an HIV-like in-
fection) and colonized with the opportunistic fungus,
Pneumocystis (Pc), develop chronic airflow obstruction
with radiographic and morphometric evidence of em-
physema and lung airspace enlargement [12]. Using this
model, we characterized bacterial microbiota changes
over the course of SHIV infection and we correlated the
bacterial microbiota with the development of COPD.
Results
Taxonomic composition of the lung microbiota
Using target gene sequencing, we analyzed the compos-
ition of the lung microbiota in the bronchoalvealoar la-
vages (BAL) of 12 cynomolgus monkeys at baseline and
over 53 weeks post-infection with the SIV-HIV chimeric
virus SHIV89.6P. The V1–V3 region of the 16S ribosomal
DNA (rDNA) was PCR-amplified and sequenced on the
Roche/454 GS-FLX sequencing platform. Reads were
clustered into operational taxonomic units (OTUs) using
DNAclust [13]. We identified 6002 OTUs present in
more than one sample with 25 to 777 OTUs per sample
(median = 341, average = 355); 82 % of the OTUs had
significant matches to 736 distinct taxa from 189 genera.
The top 9 genera present in the highest proportion in the
BALs across monkeys, and across time points, includemembers of the phyla Proteobacteria (Acinetobacter,
Neisseria, and Uruburuella), Bacteroidetes (Porphyromo-
nas, Prevotella, and Flavobacterium), Fusobacteria (Fuso-
bacterium), Firmicutes (Streptococcus), and Actinobacteria
(Tropheryma).
Surprisingly, at baseline (time points –10 or –13 weeks
before SHIV infection), a number of monkeys had BAL
microbiota dominated by the genus T. whipplei, while
other monkeys had high diversity in their microbiota
with no one genus making up more than 25 % of the
microbiota (Fig. 1). Within the higher diversity samples,
the most prevalent genera (15–25 % relative abundance)
were Streptococcus, Prophyromonas, Neisseria, and Uru-
buruella. Tropheryma-dominant monkeys had reduced
alpha diversity (average Simpson’s Index 0.76, SD = 0.08)
compared to high diversity monkeys (Simpson’s Index
0.97, SD = 0.03; Wilcoxon p = 0.009). These Tropheryma-
dominant monkeys also exhibited altered microbiota com-
position at baseline as measured by adonis/PERMANOVA
testing (p = 0.005) (Fig. 2a). Over the course of the infec-
tion, the majority of their samples continued to cluster
away from high diversity monkeys (Fig. 2a). For both
the Tropheryma-dominant and high diversity monkeys,
there was higher microbiota variation observed between
monkeys (adonis p is <0.001) at each time point than
between time points for the same monkey (variation
over time p = 0.145).
Because the monkeys were obtained from two different
colonies, we tested for a batch effect at baseline. Colony
origin did not affect alpha diversity (Wilcoxon p = 0.153),
but did affect composition (adonis/PERMANOVA p =
0.004); the Tropheryma-dominant monkeys, for example,
were found to be from the same colony. However, these
monkeys did not cluster over the course of the study
(Fig. 2b).
Taxa associated with SHIV
To explore the effect of SHIV infection on the lung
microbiota, we compared pre-infection to all post-
infection samples. We identified no taxonomic group
that had strong statistical association to SHIV status
(metagenomeSeq p < 0.05 and log2 fold change >2).
When relaxing our log2 fold change threshold, we ob-
served one OTU differentially abundant. In particular,
OTU 4802 annotated as Uruburuella suis was found to
be more abundant in pre-infected samples with a log2
fold change of −1.79. Furthermore, we did not observe
any significant correlation between microbiota profiles
and CD4 or SHIV viral levels (data not shown).
Association of lung microbiota with chronic obstructive
pulmonary disease (COPD)
We compared the lung microbiota of monkeys that de-
veloped obstructive pulmonary disease (determined by
Fig. 1 Proportion of main genera in bronchoscopic alveolar lavage (BAL). Each row is a monkey, and each column is a BAL sample. Time points
pre- and post-SHIV infection are shown above each BAL. While the microbiota of different monkeys is highly divergent, within the same monkey
the microbiota composition is relatively stable over time. Tropheryma whipplei (red) was the predominant organism in several monkeys
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Fig. 2 Principal Coordinate Analysis (PCoA). Each BAL sample is represented by a dot and the distances between dots represent the weighted
UniFrac distance between samples. During PCoA, samples were scaled down to two unit-free dimensions (coordinates) for visualization. a Tropheryma-
dominant vs high diversity monkeys. Red dots correspond to time points at which Tropheryma whipplei was the predominant organism in the BAL
sample of any monkey; circles highlight the earliest time point for each monkey (weeks −13 or −10). b Monkeys color-coded by colony from which
the monkey originated. Yellow and blue dots separate the samples collected at all time points from monkeys originating from each of the two colonies.
Colony origin does not predict microbial composition, as seen by the lack of separation of the samples based on colony
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testing) during the study period with that of monkeys
that did not (Table 1). We first investigated the potential
relationship of T. whipplei frequency and prevalence to
COPD, but did not observe an enrichment of this organ-
ism within the COPD group (Fig. 3). To determine asso-
ciations of other OTUs with COPD, we then used linear
mixed models and time-dependent Smoothing Spline
ANOVA (SSANOVA) (Additional file 1: Tables S1 and S2).
We found that OTUs belonging to several oral microbial
taxa—Fusobacterium, Prevotella,Veillonella, Neisseria, and
Porphyromonas—were enriched in the BALs of animals
that developed COPD (Fig. 4). Several potential respiratory
pathogens such as Uruburuella suis, Streptococcus sp., and
Flavobacterium sp. were enriched in the animals that did
not develop COPD.
To further explore this association, we employed SSA-
NOVA to investigate the time-related changes in the lung
microbiota in the context of airway obstruction. This test
allows us to determine not only whether a difference exists
but also at which time point the difference becomes mani-
fest. Veillonella was more abundant over the entire study
period in the lungs of monkeys that eventually developed
COPD, while Prevotella and Fusobacterium exhibited anTable 1 Demographic characteristics of macaques by chronic obstru
COPD+ (n
Age, mean (SD) 7.3 (2.9)
Female, n (%) 2 (33)
Peak viral load, mean RNA copies per ml (SD) 4.7 × 107 (
Acute phase (4 wpi) CD4+ T cells, mean (SD) 816 (663)
Chronic phase (20 wpi) CD4+ T cells, mean (SD) 888 (622)
wpi weeks post-infectionenrichment only starting at weeks 16 and 17 post-SHIV in-
fection (Fig. 4a). This period is consistent with the time
when persistent declines in pulmonary function were evi-
dent in the monkeys. Several other taxa appeared by SSA-
NOVA to be associated with COPD, including Treponema,
Catonella, and Granulicatella (Additional file 1: Table S2).
Taxonomic groups enriched in non-COPD samples
included Flavobacterium and Uruburuella, consistent
with the cross-sectional statistical findings. In addition, we
noted a decrease in Acinetobacter, Staphylococcus,
Enterococcus, Acidovorax (Fig. 4b), and Kineosporia
(Additional file 1: Table S2). Although detection of the
fungus Pneumocystis in the lungs has been shown to be
associated with COPD in this animal model, we did not
find any changes in bacterial taxa according to Pneumo-
cystis colonization status (data not shown).
Network view of SHIV+ lung microbiota
To determine whether there was an organizational
principle for the microbial community within the lung of
the monkeys over the course of SHIV infection, we inves-
tigated inter-microbial species associations by correlation
network analysis using the differential abundance data.
We built this network with SParse InversE Covariancective pulmonary disease (COPD) status
= 6) COPD− (n = 6) p value
8.8 (4.8) 0.53
2 (33) 1.00
8.8 × 107) 3.3 × 107 (2.3 × 106) 0.70
370 (276) 0.16
705 (434) 0.57
Fig. 3 Tropheryma whipplei abundance across time and clinical outcome. Abundance ranges from low (blue) to high (red) with white indicating
missing data. Monkeys were grouped by COPD status. Within each group, they are clustered by the abundance profile of Tropheryma. White and
grey boxes on the left side indicate COPD status. Tropheryma abundance was not associated with COPD
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EASI) [14]. The network demonstrated negative associa-
tions between two large groups of OTUs and positive as-
sociations within each group (Fig. 5a); singleton OTUs
(i.e., not associated with any other OTU) were removed.
In the largest group, we identify OTUs belonging to the
genera that were seen by SSANOVA to be enriched in
animals that developed COPD including Fusobacterium,
Prevotella, Veillonella, Neisseria, and Porphyromonas
(Fig. 5b). In the smallest group, we saw OTUs in the
genera identified as enriched in non-COPD animals, in-
cluding Uruburuella and Flavobacterium (Fig. 5b). Other
OTUs in this group that were not identified by the other
methods belonged to genera including Kinesporia, Entero-
coccus, and Vibrio. Most interestingly, OTUs belonging to
the Streptococcus genus were found in both groups,
highlighting its importance within both COPD and non-
COPD bacterial communities. The separation of the two
groups showed the difference in community compositionthat accompanied the development of COPD. The nega-
tive correlations between members of the two groups
emphasize how shifts in one species can impact multiple
other species, potentially resulting in disease.
Discussion
We performed a longitudinal sampling of the lung
microbiota in non-human primates over 53 weeks post-
SHIV infection. We found that there was a high degree
of variation in the microbiota of individual animals with
two apparent community types—one dominated by T.
whipplei and the other characterized by greater micro-
bial diversity. Although there were shifts in the bacterial
communities of individual monkeys over time, the com-
munity structure of an individual animal was relatively
consistent. We found that there were minimal changes
over the course of an HIV-like immunosuppression and
that relative increases in oral bacteria predominated dur-
ing development of COPD.
ab
Fig. 4 Smoothing Spline ANOVA (SSANOVA) showing progression of differential abundance of specific oral microbial taxa during the course of
infection. The y-axis represents the difference in normalized abundances of these taxa between monkeys that developed COPD and those that
did not. All monkeys were used in this analysis. Values above zero indicate an enrichment of the specific taxon in monkeys that develop COPD.
Dashed lines are the confidence intervals. The shaded area indicates time when the differences in abundance of each taxon are significant as
compared to baseline abundance (of the control group). The x-axis represents time in weeks pre-SHIV and post-SHIV infection. We highlight with
vertical lines weeks 16 and 17 when there was a decrease in pulmonary function in monkeys that developed COPD. a Taxa positively associated
with COPD. b Taxa negatively associated with the disease
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the study of the lung microbiome. Because monkeys are
outbred and have an upright posture, their lung micro-
biome is likely more similar to humans than to mice. In
addition, the model overcomes difficulties encountered
in human lung microbiome studies such as the inability
to perform frequent lower lung sampling, the influence
of other factors such as smoking, diet, and medication
use, and easier access to the lung with potentially less
oral contamination. This study is the first to report on
longitudinal changes in the lung microbiota in any ani-
mal model. Although human studies have reported serial
bronchoscopies or frequent sputum specimens, perform-
ance of monthly bronchoscopies is not possible in
humans; thus, this study provides data that have direct
relevance to the study of the human lung microbiome.
In the lung, there were greater differences betweenanimals than within the same animal over time; however,
individual animals did have samples that differed from
their baseline community structure at certain time
points. Other studies have shown that the stability of the
microbiome is dependent on the body site sampled, with
the oral microbiome being less stable over time than, for
example, the vaginal microbiome [15]. Similar longitu-
dinal analyses have not been done for the lung.
The monkeys were infected with SHIV and developed
a HIV-like immunosuppression over the course of the
study. We were thus able to study pre- and post-SHIV
infection, which is challenging in human HIV studies.
This allowed us to evaluate shifts in the bacterial com-
position of the lung prior to and after infection, as well
as during development of COPD, defined as develop-
ment of fixed airway obstruction. While we found alter-
ations in several bacteria, no large shifts were observed
Fig. 5 Correlation network analysis using SPIEC-EASI. a The ecological correlation network shows two groups of OTUs that are negatively correlated
with each other. One group includes OTUs identified as enriched in COPD animals (COPD+) and the other includes OTUs enriched in non-COPD
animals (COPD−). Each node represents an OTU and is colored by its assigned taxonomy. Green edges represent positive correlation between OTUs
and red represent negative correlation. b Negative edges have been removed to show that the two groups have no positive correlations with each
other. This separation emphasizes the shift in community composition that occurred when an animal developed COPD
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fection. Similar findings have been reported by the Lung
HIV Microbiome Project that described changes in the
oral microbiome in HIV-infected individuals compared
to HIV-uninfected controls, but fewer differences in the
lung microbiota [16]. Whether changes in the lung
microbiome occur prior to, or during, opportunistic lung
infections or with profound immunosuppression in this
animal model of human disease is unknown.
Interestingly, some monkeys had in their lungs a
predominance of T. whipplei, the etiologic agent of
Whipple’s disease, which persisted over the course of the
study while others demonstrated transient colonization.
These findings may be similar in humans where some in-
dividuals have been reported to have high levels of T.
whipplei in BAL, although whether T. whipplei persists is
not known [5, 17, 18]. In a recent study, T. whipplei was
reported to be more prevalent in individuals who smoked
or were HIV-infected [5], while another study showed no
correlation with HIV [19]. In our non-human primate
model, we found that T. whipplei was actually more com-
mon prior to SHIV infection. These differences may result
from environmental variations, may be due to biological
differences between monkeys and humans or a result fromrandom sampling. There was also no relationship of T.
whipplei to the development of COPD in the animals.
We found by cross-sectional statistics and by network
analysis that several oral microbial taxa, such as Fuso-
bacterium, Prevotella, Veillonella, Neisseria, and Por-
phyromonas, were enriched in the BALs of SHIV-
infected animals that developed COPD. Oral bacteria
have previously been implicated in COPD pathogenesis
in humans who smoke [18], but have not been reported
in an HIV-associated model. Furthermore, changes in
the lung prior to development of COPD in humans have
not been assessed. With the exception of Neisseria, all
these organisms are anaerobes and have been associated
with periodontal diseases and infections of the respiratory
tract [20–22]. While specific oral bacteria have previously
been found to be associated with airway obstruction in
smokers [18], they had not yet been reported in a non-
smoking population. These alterations in bacterial
prevalence suggest that failure to clear oral anaerobes after
aspiration may be a common mechanism in these types of
lung diseases. Whether treatment of these organisms
would prevent or improve COPD is unknown.
There are several limitations of the study. First, as with
any study of the lung microbiome, we are examining a
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concern. We also could not account for bronchoscopic
carryover from the mouth as we did not collect oral sam-
ples in parallel. As the monkeys are deeply sedated at the
time of bronchoscopy, insertion of the bronchoscope is
easier, limiting contact with the oral cavity. Second, we are
primarily focusing on the bacterial taxonomy of the lung.
Viruses or fungi may play a role, and functional aspects of
the microbiome are likely important.
Conclusions
In summary, this study is the first to contribute detailed
information on monthly changes in the lung over a long
time period in a model directly relevant to humans. The
lung microbiome demonstrated variability between nor-
mal animals at baseline with relatively less variation over
time, despite development of immunosuppression. The
study is also the first to investigate changes in the lung
prior to development of COPD in a non-smoking model
and found that persistence of oral microbes were associ-
ated with the development of COPD. The exact role of
these bacteria in COPD pathogenesis is currently un-
known, but similar data in humans suggest a potential
mechanistic role. The lung microbiome in the non-human
primate is a valuable tool for examining the impact of the
lung microbiome in human health and disease.
Methods
Animals
Adult Chinese-origin, cynomolgus macaques (Macacca fas-
icularis) were procured from the University of Pittsburgh
Department of Laboratory Animal Research-approved ven-
dors. Macaques were housed in the University of Pittsburgh
non-human primate facility, which is accredited by the
American Association for Accreditation of Laboratory
Animal Care. Animal care and husbandry was provided
in accordance with standards set forth in the Guide for
the Care and Use of Laboratory Animals [23]. All ex-
perimental animal procedures were approved by the
University of Pittsburgh Institutional Animal Use and
Care committee (approval number 08103308) prior to
the start of the study, and were in full compliance with
the Provisions of the Animal Welfare Act, and other
applicable laws and regulations.
SHIV infection
Cynomolgus macaques (n = 12) were inoculated with
SHIV89.6P. All were continuously exposed to Pneumocys-
tis via cohousing with simian immunodeficiency virus
(SIV) and Pneumocystis co-infected macaques. Natural
airborne transmission of Pneumocystis in this model sys-
tem has been previously described [12, 24]. Demo-
graphic characteristics of animals are given in Table 1.
Pulmonary function tests were performed at baseline(pre-SHIV infection) and every other month after SHIV
infection (up to 12 months post-infection) by use of
whole body plethysmography and forced deflation tech-
nique on anesthetized monkeys, as described [12].
SHIV-infected monkeys that became colonized with
Pneumocystis (n = 6) had evidence of obstructive pul-
monary disease, which was defined by a decrease in the
post-bronchodilator forced expiratory volume in 0.4 s
[12]. Forced expiratory volume was obtained by per-
forming whole body plethysmography, similar to human
pulmonary function; decreases in this measure indicate
development of airway obstruction. These animals also
developed emphysema as determined by quantitative
high resolution computed tomography scanning, and tis-
sue morphometry [12].
Lung microbiome sampling
Prior to each bronchoscopy, the bronchoscope was
washed using Enzol enzymatic detergent (Johnson and
Johnson Medical, New Brunswick, NJ), rinsed with
water, and placed in a sterilizing bath of 2.5 % glutaral-
dehyde solution for at least 15 min. The bronchoscope
was passed through the laryngeal folds and directed into
the right main stem bronchus without suction. Once
wedged, four aliquots of 10 ml sterile saline were lavaged.
Bronchoalveolar lavage (BAL) fluid was immediately
placed on ice and transported to the laboratory for pro-
cessing. Unfractionated BAL fluid was filtered through a
40-μm-pore-size cell strainer (BD Falcon, Franklin Lakes,
NJ). Lung cells were pelleted (5 min at 500g), and super-
natant fluid was collected and stored at −80 °C until use.
Sample processing and sequence library preparation
Raw BALs supernatants were spun at 10,000g and frozen
at −80 °C. Pellets were resuspended in 180 μl of freshly
prepared lysozyme solution (20 mg/ml lysozyme, 20 mM
Tris-Cl, pH 8.0, 2 mM Na-EDTA, 1.2 % Triton X-100,
filtered through a 0.22-μm filter) and incubated at 37 °C
for 10 min. Extraction followed the Qiagen DNEasy
Blood and Tissue kit protocol. Reagent controls, without
BAL, were also processed through the Qiagen proced-
ure. Extracted DNA was used in a PCR reaction with
Roche/454 GS-FLX sequencing adapter fusion primers
targeting the V1–V3 region of the bacterial 16S riboso-
mal RNA (rRNA). The reaction mix consisted of 0.75 U
Accuprime Taq Hifi, 1× Accuprime PCR buffer II,
1 μl DNA sample, and 200 nmol of barcoded primer.
Cycling conditions were 95 °C for 2 min, then 30 cycles of
95 °C for 20 s, 56 °C for 30 s, and 72 °C for 5 min. Reac-
tions were cleaned up using 36 μl of Ampure Beads
(Agencourt) and eluted into 25 μl low TE, pH 8.0. Eluted
PCR products were quantitated in triplicate using DNA
Picogreen (Invitrogen). Two final sample pools were cre-
ated by combining 103 and 104 total PCRs; each positive
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ple (buffer) had 20 μl added. The combined pools were
then purified on a MinElute PCR column (Qiagen) and
eluted into TE buffer. A total of 170 BAL samples were
multiplexed in this manner in two separate gasket wells.
Sequencing and data analysis
Sequencing was performed on the Roche/454 GS-FLX
sequencer using Titanium chemistry (1,034,190 total raw
sequences), with an average read length of 400 bp.
Sequences that were too short (<75 cycles of the 454 in-
strument) or that contained at least one unrecognizable
barcode (‘N’) were filtered from the data. Barcoded
sequences were deconvoluted and reads were trimmed.
Sequencing of PCR-amplified 16S rRNA genes resulted
in 668,353 reads passing quality checks. Reads were
clustered into 132,234 operational taxonomic units
(OTUs) using DNAclust [13]. Only 6002 OTUs were de-
tected in more than five samples or represented at least
20 sequences in a single sample and were included in
further analysis. The number of OTUs per sample
ranged from 25 to 777, with a median of 341 and an
average of 355. The mean OTU size was 77, ranging
from 5 to 59,920 with a median of 18 sequences. Repre-
sentative sequences from the 6002 OTUs matched 736
distinct taxa from 189 genera. Among these, 1104 (18 %)
did not have good matches (>100 bp exact match, >97 %
identity) to isolate sequences from the RDP database
(version 10.4). These were flagged as ‘no match’ in our
analysis and assigned an OTU identifier. The resulting
data were organized in a collection of tables at different
taxonomic levels containing each taxonomic group as a
row and each sample as a column. These tables formed
the substrate for statistical analyses.
Statistical analyses
Differential abundance was assessed with the Bioconduc-
tor package, metagenomeSeq [25]—a statistical method
to incorporate the effect of under-sampling on the ob-
served counts. Significant findings were reported for
OTUs that satisfied the following criteria: (i) OTU had
log2 fold change exceeding 2 in either cases or controls
except in testing obstruction where we relaxed our
threshold to a log2 fold change of 1; and (ii) statistical
association was significant (p < 0.05) after Benjamini-
Hochberg correction for multiple testing [26]. To test
the shifts in abundance for specific taxa due to COPD,
we employed Smoothing Spline ANOVA (SSANOVA)
methods. To test for differentially abundant time intervals,
we fit a smoothing spline on the difference in abundance
between animals that developed COPD and animals that
did not, and calculated 95 % Bayesian confidence intervals
under the SSANOVA framework. This procedure esti-
mates a function of the difference in abundance acrosstime for each taxon. The SSANOVA procedure also in-
cluded time, obstruction status and their interaction
(http://cbcb.umd.edu/software/metagenomeSeq) [27]. We
assumed an alpha of 0.2. Analyses were performed using
the R software package 3.0.1 (http://www.R-project.org/)
and metagenomeSeq 1.12.0 [25]. We fit a linear mixed
model for each OTU independently to account for indi-
vidual monkey variability while controlling for sampling
day. We also included the cumulative sum scaling (CSS)
normalization factor as a covariate in our linear mixed
models. In the significance testing for our models, we
retained only OTUs where the estimated Wald-type
confidence intervals agreed in sign with each other.
For fitting the models, we used the R package lme4
version 1.1-8 [28, 29].
Ecological network construction
Ecological correlation networks were constructed on the
94 OTUs present in more than one-third of the samples
(56 or more samples). Each network was built using
SParse InversE Covariance estimation for Ecological AS-
sociation Inference (SPIEC-EASI) [14]. The final net-
work was selected by random subsampling and
interaction re-estimation using the Stability Approach to
Regularization Selection (StARS) [30] with a 0.1 variabil-
ity threshold. For visualization, OTUs outside the con-
nected component were removed.
Additional file
Additional file 1: Table S1. Estimates from a linear mixed model
comparing taxa abundance between COPD+ and COPD− samples. Fold
change estimates and basic statistics of several OTUs comparing COPD+
and COPD− samples 20 days after infection. In the linear mixed model,
we accounted for individual monkey effects, days sampled, and included
normalization factors. We filtered OTUs to those with at least 100 counts
and declared OTUs significant if lower and upper log fold change
estimates agreed in directionality. Row colors represent enrichment,
green in COPD− and red in COPD+ samples. Table S2 Smoothing Spline
ANOVA estimates comparing COPD+ and COPD− taxa abundances
through time. Smoothing Spline ANOVA estimates of the difference in
genera abundances between COPD+ and COPD− groups through time.
To test for differentially abundant time intervals, we fit a smoothing
spline and calculated 95 % Bayesian confidence intervals under the
SSANOVA framework. The SSANOVA procedure also included time,
obstruction status and their interaction. We estimate significance using a
permutation procedure and calculate significance with area under the
curve as our test statistic. Row colors represent enrichment, green in
COPD− and red in COPD+ samples. (XLSX 52 kb)
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